TG Therapeutics, Inc.
TGTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $5,281 | $5,784 | $4,374 |
| - Cash | – | $129 | $132 | $180 |
| + Debt | – | $254 | $255 | $254 |
| Enterprise Value | – | $5,406 | $5,906 | $4,449 |
| Revenue | $162 | $141 | $121 | $108 |
| % Growth | 14.6% | 16.8% | 11.7% | – |
| Gross Profit | $134 | $122 | $105 | $93 |
| % Margin | 82.6% | 86.6% | 87.1% | 85.8% |
| EBITDA | $33 | $38 | $12 | $33 |
| % Margin | 20.2% | 26.7% | 10.2% | 30.1% |
| Net Income | $391 | $28 | $5 | $23 |
| % Margin | 241.7% | 20% | 4.2% | 21.6% |
| EPS Diluted | 2.428 | 0.17 | 0.031 | 0.15 |
| % Growth | 1,328.2% | 446.6% | -79.3% | – |
| Operating Cash Flow | – | $7 | -$29 | -$26 |
| Capital Expenditures | – | -$0 | -$0 | -$0 |
| Free Cash Flow | – | $7 | -$29 | -$26 |